Table 3b Contralateral breast cancer incidence after the start of follow-up, which is at the date of mutation testing or date of CPM

From: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers

Outcome and follow-up

CPM group ( N =75)

Surveillance group ( N =43)

P -value

Follow-up mean±s.e. (years)

 Until contralateral breast cancer, death or end of follow-up

3.4±0.2

3.1±0.3

0.440

Contralateral breast cancer

 N (%)

1a (1.3)

6b (14)

0.009

 Time until occurrence (years)

1.6

2.2±0.8

 
  1. CPM=contralateral prophylactic mastectomy; s.e.=standard error of the mean.
  2. aThree ductal carcinoma in situ and one invasive breast cancers found after histological examination in the CPM were excluded.
  3. bContralateral breast cancers that occurred before the date of mutation testing (n=26) were excluded.
Back to article page